Multi-Stakeholder Call to Action for the Future of Vaccine Post-Marketing Monitoring: Proceedings from the First Beyond COVID-19 Monitoring Excellence (BeCOME) Conference

Affiliations

• ¹ Independent, Previously GSK, Vaccine Safety, Wavre, Belgium.
• ² P95 (Epidemiology and Pharmacovigilance Consultant and Services), Leuven (Flemish Brabant), Belgium.
• ³ GSK (Safety Evaluation and Risk Management), London, UK.
• ⁴ Murdoch Childrens Research Institute, University of Melbourne, Melbourne, VIC, Australia.
• ⁵ Janssen Research and Development LLC (Global Epidemiology), Horsham, PA, USA.
• ⁶ Brighton Collaboration (A Program of the Task Force for Global Health), Decatur, GA, USA.
• ⁷ World Health Organization, Geneva, Switzerland.
• ⁸ Pfizer (Worldwide Medical & Safety), New York, NY, USA.
• ⁹ AstraZeneca (Global Patient Safety), Mississauga, ON, Canada. [email protected].
• ¹⁰ Sanofi (Global Pharmacovigilance), Toronto, ON, Canada.
• ¹¹ US Food and Drug Administration (Center for Biologics Evaluation and Research), Silver Spring, MD, USA.
• ¹² Sanofi (Patient Safety and Pharmacovigilance), Lyon, Auvergne-Rhone-Alpes, France.
• ¹³ Sanofi (Epidemiology and Benefit Risk), Bridgewater, NJ, USA.
• ¹⁴ Independent, Previously Bill & Melinda Gates Foundation (Safety & Pharmacovigilance), London, UK.
• ¹⁵ Sanofi (Epidemiology and Benefit Risk Evaluation), Lyon, Auvergne-Rhone-Aples, France.
• ¹⁶ AstraZeneca (Medical Evidence, Vaccines & Immune Therapies), Cambridge, UK.
• ¹⁷ Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
• ¹⁸ Thriive.AI, Bronx, NY, USA.
• ¹⁹ National Institute for Health and Welfare (Infectious Diseases Control and Vaccines), Helsinki, Finland.
• ²⁰ School of Public Health (Department of International Health, Institute for Vaccine Safety), Johns Hopkins Bloomberg, Baltimore, MD, USA.
• ²¹ Novavax (Safety Science and Surveillance), Gaithersburg, MD, USA.
• ²² Sanofi (Vaccines Medical Global Evidence Generation Influenza), Lyon, Auvergne-Rhone-Alpes, France.